Current status of transarterial radioembolization

Table 4 Summary of randomized controlled clinical trials comparing different treatments to ⁹⁰Y-transarterial radioembolization using resin spheres in colorectal liver metastases

Ref.	Patients (n)	Protocol	Design	Setting	Response (%)					Progression free survival (mo)	Median survival (mo)
					CR	PR	SD	AR	PD
Gray et al[19]	36	TARE + HAI FUDR	RCT - Phase III	Early line	6	44	28	78	14	15.9 (liver)	17
	34	TARE - HAI FUDR			0	22	48	70	30	9.7 (liver)	15.9
Van Hazel et al[21]	11	TARE + 5-FU/LV	RCT - Phase II	1. line	0	91	9	100	0	18.6	29.4
	10	5-FU/LV			0	0	60	60	40	3.6	12.8
Hendlisz et al[20]	21	TARE + 5-FU	RCT - Phase III	Salvage	0	10	80	90	10	4.5	10
	23	5-FU			0	0	36	36	64	2.1	7.3
Gibbs et al[24]	267	TARE + FOLFOX ± Bevacizumab	RCT - Phase III	1. line	4.5	71.9	NA	NA	NA	10.7/20.5 (liver)	NA
	263	FOLFOX ± Bevacizumab			1.5	66.5	NA	NA	NA	10.2/12.6 (liver)	NA

CR: Complete response; PR: Partial response; SD: Stable disease; AR: Any response; PD: Progressive disease; NA: Not available; RCT: Randomized controlled clinical trial; HAI: Hepatic artery infusion; FUDR: Floxuridine; TARE: Transarterial radioembolization; 5-FU: 5-fluoruracil; LV: Leucoverin.